Home/Pipeline/PDS0101 + PDS01ADC

PDS0101 + PDS01ADC

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

PDS Biotechnology

About PDS Biotechnology

PDS Biotech is a clinical-stage company developing next-generation immunotherapies based on its proprietary Versamune® T-cell activating platform and PDS01ADC tumor-targeted IL-12. The company has generated compelling Phase 2 data in HPV-positive head and neck cancer, demonstrating significant tumor shrinkage and extended survival, and has now initiated a pivotal Phase 3 trial. Its strategy centers on advancing its lead asset, PDS0101, towards commercialization in HPV-associated cancers while exploring platform applications in other cancers and infectious diseases through strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active
FS222	F-star Therapeutics	Phase 1	Active (status post-acquisition)
FS120	F-star Therapeutics	Phase 1	Active (status post-acquisition)
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active